Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

June 07, 2017

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 04, 2019

    Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling

    The Federal Circuit on Friday said it wouldn't reconsider the invalidation of four patents covering Acorda Therapeutics Inc.'s flagship multiple sclerosis drug Ampyra, despite the drugmaker's argument that the decision had "radically expand[ed]" the so-called blocking patent doctrine.

4 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login